Changes in Serum PINP and β-CTX Levels before and after Glucocorticoid Therapy in Patients with Systemic Lupus Erythematosus and Their Clinical Significance

This study aims to elucidate the characteristics of bone metabolic imbalance and its clinical significance as reflected by the changes in serum PINP and β-CTX levels before and after glucocorticoid therapy in patients with systemic lupus erythematosus (SLE). The results indicate a rapid decline in PINP levels during the early phase of treatment, suggesting a marked suppression of bone formation, while β-CTX levels, though showing delayed elevation in some cases, remained indicative of active bone resorption overall, demonstrating that a bidirectional imbalance in bone metabolism had already developed as a systemic stress response in the short term. Analysis of these biomarkers contributes to the establishment of individualized bone health monitoring models for SLE patients, providing an evidence-based foundation for risk management during glucocorticoid therapy.